# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

> **NCT05048849** · PHASE2 · COMPLETED · sponsor: **Medigen Vaccine Biologics Corp.** · enrollment: 274 (actual)

## Conditions studied

- Covid19 Vaccine

## Interventions

- **BIOLOGICAL:** MVC-COV1901(S protein with adjuvant)

## Key facts

- **NCT ID:** NCT05048849
- **Lead sponsor:** Medigen Vaccine Biologics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-19
- **Primary completion:** 2021-11-08
- **Final completion:** 2022-04-12
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048849, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05048849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*